OPKO HEALTH, INC. - 8-K Filing
OPKO Health reports Q3 2026 continuing operations revenue of $65.4 million and announces agreement to sell BioReference diagnostic operations to Labcorp for up to $872 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $OPK